—
— Management to Hold Conference Call Today at
“The positive results of ENLIGHTEN-1 provide clear evidence of the
safety, tolerability and antipsychotic efficacy of ALKS 3831 in a large,
randomized registration trial,” said
“Many physicians recognize the powerful efficacy profile of olanzapine,
but are hesitant to prescribe it given the severe weight gain and
metabolic side effects commonly associated with its use,” said
Overall, 91% of patients who received ALKS 3831 completed the study, compared to 89% of patients who received olanzapine and 83% of patients who received placebo. The most common adverse events for both the ALKS 3831 and olanzapine treatment groups were weight gain, somnolence and dry mouth.
About the ENLIGHTEN-1 Study
ENLIGHTEN-1
was a multinational, double-blind, randomized, phase 3 study that
evaluated the antipsychotic efficacy, safety and tolerability of ALKS
3831 compared to placebo over four weeks in patients experiencing an
acute exacerbation of schizophrenia. The study also included a
comparator arm of olanzapine, an established atypical antipsychotic
agent with proven efficacy but also metabolic liabilities, including
significant weight gain.1 The trial included adult patients
who met the Diagnostic and Statistical Manual of Mental Disorders –
Fifth Edition criteria for schizophrenia, and had a PANSS score of
80 or higher at study baseline.
A total of 403 patients were randomized in a 1:1:1 manner to receive once-daily, oral tablets of ALKS 3831, olanzapine or placebo for four weeks. Patients randomized to the ALKS 3831 treatment group received a bilayer fixed-dose tablet of 10 mg samidorphan co-formulated with either 10 or 20 mg of olanzapine. Patients randomized to the olanzapine treatment group received either 10 or 20 mg of olanzapine. The primary efficacy endpoint of the study was the mean change from baseline at Week 4 in PANSS total score for ALKS 3831 compared to placebo, using a Mixed Model with Repeated Measurements (MMRM) model. The key secondary endpoint of the study was change from baseline in the CGI-S score at Week 4.
All participants who completed the double-blind portion of the study were eligible to continue in an open-label, long-term safety study and receive ALKS 3831 for an additional 12 months. The objective of the extension phase of the study is to assess the long-term safety, tolerability and durability of effect of ALKS 3831.
Conference Call
About the ENLIGHTEN Clinical Development Program
The
ENLIGHTEN clinical development program for ALKS 3831 is comprised of two
key studies: a study evaluating the antipsychotic efficacy of ALKS 3831
compared to placebo over four weeks and a study assessing weight gain
with ALKS 3831 compared to olanzapine in patients with schizophrenia
over six months. The program also includes supportive studies to
evaluate the pharmacokinetic and metabolic profile of ALKS 3831, the
effect on body weight of ALKS 3831 in young adult patients early in
their illness, and long-term safety.
About ALKS 3831
ALKS 3831 is a
proprietary, investigational medicine designed as a broad-spectrum
antipsychotic for the treatment of schizophrenia. ALKS 3831 is composed
of samidorphan, a novel, new molecular entity co-formulated with the
established antipsychotic agent, olanzapine, in a single bilayer tablet.
Weight gain is a common and clinically relevant metabolic side effect of atypical antipsychotic medications, and olanzapine, commercially available as ZYPREXA®, has one of the highest incidences and greatest amounts of weight gain among the widely prescribed products in this class of drugs.1 ALKS 3831 is designed to provide the strong antipsychotic efficacy of olanzapine and a differentiated safety profile with favorable weight and metabolic properties.
About Schizophrenia
Schizophrenia
is a chronic, severe and disabling brain disorder. The disease is marked
by positive symptoms (hallucinations and delusions) and negative
symptoms (depression, blunted emotions and social withdrawal), as well
as by disorganized thinking. An estimated 2.4 million American adults
have schizophrenia,2 with men and women affected equally.
About
Note Regarding Forward-Looking Statements
Certain
statements set forth in this press release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including, but not limited to,
statements concerning: the timing of receipt and reporting of the phase
1 metabolic and ENLIGHTEN-2 study results; and the therapeutic value,
development plans and commercial potential of ALKS 3831. You are
cautioned that forward-looking statements are inherently uncertain.
Although the company believes that such statements are based on
reasonable assumptions within the bounds of its knowledge of its
business and operations, the forward-looking statements are neither
promises nor guarantees and they are necessarily subject to a high
degree of uncertainty and risk. Actual performance and results may
differ materially from those expressed or implied in the forward-looking
statements due to various risks and uncertainties. These risks and
uncertainties include, among others: whether preclinical and clinical
results for ALKS 3831 will be predictive of future clinical study
results; whether the ENLIGHTEN-2 study for ALKS 3831 will be completed
on time or at all; potential changes in cost, scope and duration of the
ALKS 3831 clinical development program; whether ALKS 3831 could be shown
ineffective or unsafe during clinical studies; and those risks and
uncertainties described under the heading “Risk Factors” in the
company’s Annual Report on Form 10-K for the year ended
ZYPREXA® is a registered trademark of
1Komossa, K. et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews. 2010, Issue 3. Art. No.: CD006654.
2
View source version on businesswire.com: http://www.businesswire.com/news/home/20170629006201/en/
Source:
Alkermes plc
For Investors:
Eva Stroynowski, +1 781-609-6823
or
Sandy
Coombs, +1 781-609-6377
or
For Media:
Jennifer Snyder, +1
781-609-6166